Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function: Results of an observational study

Journal of Public Health (Germany)

Volumn 22, Issue 2, 2014, Pages 89-99

  Boettger, Bjoern ^a   Wehling, Martin ^b   Bauersachs, Rupert M ^c   Amann, Steffen ^d   Wilke, Thomas ^a  

^a Institute for Pharmacoeconomics and Medication Logistics   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KLINIKUM DARMSTADT   (Germany)

^d Staedtisches Klinikum Muenchen   (Germany)

Author keywords

Heparins; Low molecular weight; Renal insufficiency; Summary of product characteristics; Unfractionated heparins; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; CERTOPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; FEMALE; GERMANY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; VENOUS THROMBOEMBOLISM;

EID: 84902005885     PISSN: 09431853     EISSN: 16132238     Source Type: Journal    
DOI: 10.1007/s10389-013-0598-z     Document Type: Article

References (48)

1. Abbott Arzneimittel GmbH (2012) Summary of product characteristics. Clivarin https://portal.dimdi.de/amispb/doc/2012/08/17/2162678/ OBFM42B8DB4301CD7C3E.rtf. Accessed 20 June 2013
2. Al Dieri R,Alban S,Béguin S,Hemker HC 2006 Fixed dosage of lowmolecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 4 1):83-89
3. Barras MA, Duffull SB, Atherton JJ, Green B (2008) Individualized compared with conventional dosing of Enoxaparin. Clin Pharmacol Ther 83(6):882-888 (Pubitemid 351704919)
4. Barras MA, Duffull S B, Atherton JJ, Green B (2010a) Individualized dosing of Enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. Ther Drug Monit 32(4):482-488
5. Barras MA, Kirkpatrick CM, Green B (2010b) Current dosing of lowmolecular-weight heparins does not reflect licensed product labels: an international survey. Br J Clin Pharmacol 69(5):520-528
6. Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, Melzer N, Bramlage P, Riess H (2011) CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost 105(6):981-988
7. Blix HS,Viktil KK,Moger TA, ReikvamA (2006) Use of renal risk drugs in hospitalized patients with impaired renal function: an underestimated problem? Nephrol Dial Transplant 21(11):3164-3171 (Pubitemid 44567089)
8. Bueller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW (2004) Fondaparinux or Enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140:867-873
9. Cenik BK, Sun H, Gerber DE (2013) Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer 80(3):326-332
10. Clegg LX, Potosky AL, Harlan LC, Hankey BF, Hoffman RM, Stanford JL, Hamilton AS (2001) Comparison of self-reported initial tre atment with medical records for the Prostate Outcomes Study. Am J Epidermiol 154:582-587 (Pubitemid 32867958)
11. Cockcroft DW, GaultMH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
12. Cook D, Douketis J, MeadeM, Guyatt G, Zytaruk N, Granton J, Skrobik Y, Albert M, Fowler R, Hebert P, Pagliarello G, Friedrich J, Freitag A, Karachi T, Rabbat C, Heels-Ansdell D, Geerts W, Crowther M, Group CCCT (2008) Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care 12( 2):R32
13. Crowther M, LimW(2007) Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 13(5): 409-413 (Pubitemid 47472303)
14. Deutsche Gesellschaft fü r Angiologie (DGA), Dt. Ges. für Chirurgie (DGCh), der Dt. Ges. für Gefäβchirurgie (DGG), der Dt. Ges. für Gynä kologie und Geburtshilfe (DGGG), der Dt. Ges. für Hämatologie und Onkologie (DGHO), der Dt. Ges. für Internistische Intensivmedizin und Notfallmedizin (DGII N), der Dt. Ges. für Kardiologie (DGK), der Dt. Ges. für Phlebologie (DGP), der Dt. Ges. für Pneumologie und Beatmungsmedizin (DGP), der Dt. Rö ntgengesellschaft (DRG), der Dt. Ges. für Thrombose und Hämostase (GTH) und der Dt. Ges. für Ultraschall in der M edizin (DEGUM) (2010) Diagnostik und Therapie der Venenthrombose und der Lungenembolie. AWMFLeitlinien-Register Nr. 065/ 002. Stand 06/2010. http://www.awmf.org/uploads/tx-szleitlinien/065-002-S2- Diagnostik-und-Therapie-der-Venenthromb ose-und-der-Lungenembolie-06-2010-2-. pdf. Accessed 19 June 2013
15. GlaxoSmithKline GmbH & Co. KG (2010) Summary of product characteristics. Fraxiparine. https://portal.dimdi.de/amispb/doc/2010/05/26/ 2140533/OBFMCE9E3D5D01CAF6 EA.rtf. Accessed 20 June 2013
16. GlaxoSmithKline GmbH & Co. KG (2011) Summary of Product Characteristics. Arixtra http://us.gsk.com/products/assets/us-Arixtra.pdf. Accessed 20 June 2013
17. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schü nemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):7S-47S
18. Hoffmann P, Keller F (2012) Increased major bleeding risk in patients with kidney dysfunction receiving Enoxaparin: a meta-Analysis. Eur J Clin Pharmacol 68(5):757-765
19. Holweger K, Bokemeyer C, Lipp HP (2005) Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol 131:559-567 (Pubitemid 41558547)
20. Kaneva K, Bansal V, Hoppensteadt D, Cunanan J, Fareed J (2013) Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease. Clin Appl Thromb Hemost 19(4):449-452
21. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H,Goldhaber SZ,NelsonME,Wells PS, GouldMK, Dentali F, CrowtherM, Kahn SR (2012) Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S-e494S
22. Kravitz MS, Mishaal RA, Shoenfeld Y (2005) Renal failure and low molecular weight heparins: a dangerous liaison? The case of retroperitoneal hematoma. Isr Med Assoc J 7(9):600-601 (Pubitemid 41309230)
23. KubitzaD, BeckaM, MueckW, HalabiA ,Maatouk H, KlauseN, Lufft V, Wand DD, Philipp T, Bruck H (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70(5):703-712
24. Lensing AW,Prins MH,Davidson BL,Hirsh J 1995 Treatment of deep venous thrombosis with low-molecular-weight heparins: a metaanalysis. Arch Intern Med 155 6 601-607
25. Leo Pharmaceutical Products LTD A/S (2010) Summary of product characteristics. Innohep. https://portal.dimdi.de/amispb/doc/2012/02/29/2143857/ OBFMA4115B8C01CB9E53.rtf. Accessed 20 June 2013
26. Levey AS, Bosch JP, Lewis JB , Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serumcreatinine: a new prediction equation-modification of diet in renal disease study group. Ann Intern Med 130:4 61-470 (Pubitemid 29135798)
27. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604-612
28. Lim W (2008) Low-molecular-weight heparin in patients with chronic renal insufficiency. Intern Emerg Med 3(4):319-323
29. Lim W, Dentali F, Eikelboom JW, Crowther MA (2006a ) Meta-Analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144(9):673-684 (Pubitemid 46780653)
30. Lim WH, Lim EM, McDonald S (2006 b ) Lean body mass-Adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine. Nephrology (Carlton) 11(3):250-256 (Pubitemid 43829447)
31. Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF, Allon M, Beasley TM (2010) Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 56(5):823-831
32. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT (2010) Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5( 6):1003-1009
33. Monreal M, Falgá C, Valle R, Barba R, Bosco J, Beato JL, Maestre A, Investigators RIETE (2006) Venous thromboembolism in patients with renal insufficiency: findings from the RIET E Registry. Am J Med 119(12):1073-1079 (Pubitemid 44834366)
34. Nagge J, Crowther M, Hirsh J (2002) Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162(22):2605-2609 (Pubitemid 35453500)
35. Nicolaides A, Hull RD, Fareed J (2013) Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence). Clin Appl Thromb Hemost 19(2):116-118
36. Novartis Pharma GmbH (2012) Summary of product characteristics. Mono-Embolex. http://www.fachinfo.de/pdf/00/34/003413.pdf. Accessed 20 June 2013
37. Pfizer Pharma GmbH (2010) Summary of product characteristics. Fragmin. http://news.doccheck.com/uploads/assets/articles/204308/FI%20Fragmin%207%20500- 18%20000%20I%20E%20-Sep2010.pdf. Accessed 20 June 2013
38. Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Grave M, Patek F, DrexlerM, Siemens HJ, Harenberg J,Weidinger G, Brom J, Haas S (2003) Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated h eparin in patients with proximal deep venous thrombosis. Thromb Haemost 90:252-259 (Pubitemid 36992501)
39. Rudd KM, Phillips EM (2013) New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. Thromb 2013:973710. doi:10.1155/2013/973710
40. Salomon L, Deray G, JaudonMC, Chebassier C, Bossi P, Launay-Vacher V, Diquet B, Ceza JM, Levu S, Brücker G, Ravaud P (2003) Medi cation misuse in hospitalized patients with renal impairment. Int J Qual Health Care 15(4):331-335 (Pubitemid 36987271)
41. Sanofi-Aventis Deutschland GmbH (2011) Summary of product characteristics. Clexane. http://mein.sanofi.de/ind ex.php?ID=285&cmd= getFile&getFile-cid=0900972f80043d8a. Accessed 20 June 2013
42. Schmid P, Fischer AG, Wuillemin WA (2009) Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 139(31 -32):438-452
43. Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn. Chest 133:257S-298S (Pubitemid 351892969)
44. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, Gore JM, Goldberg RJ (2009) Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism: T he Worcester VTE study. J Thromb Thrombolysis 28(4):401-409
45. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, Manthous CA (2004) Anticoagulation in ho spitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 125(3):856-863 (Pubitemid 38367274)
46. Torbicki A,Perrier A,Konstantinides S,Agnelli G,Galié N,Pruszczyk P,Bengel F,Brady AJ,Ferreira D,Janssens U,Klepetko W,Mayer E,Remy-Jardin M,Bassand JP ESC Committee for Practice Guidelines (CPG 2008 Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29 18 2276-2315
47. van den Belt AG, PrinsMH, Lensing AW, C astro AA, Clark OA, Atallah AN, Burihan E (2000) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000(2): CD0011 00
48. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW (2004) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004(4):CD001100